Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD8+ T-cell response promotes evolution of hepatitis C virus nonstructural proteins.
Ruhl M, Knuschke T, Schewior K, Glavinic L, Neumann-Haefelin C, Chang DI, Klein M, Heinemann FM, Tenckhoff H, Wiese M, Horn PA, Viazov S, Spengler U, Roggendorf M, Scherbaum N, Nattermann J, Hoffmann D, Timm J; East German HCV Study Group. Ruhl M, et al. Gastroenterology. 2011 Jun;140(7):2064-73. doi: 10.1053/j.gastro.2011.02.060. Epub 2011 Mar 2. Gastroenterology. 2011. PMID: 21376049
Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C.
Teuber G, Pascu M, Berg T, Lafrenz M, Pausch J, Kullmann F, Ramadori G, Arnold R, Weidenbach H, Musch E, Junge U, Wiedmann KH, Herrmann E, Zankel M, Zeuzem S. Teuber G, et al. Among authors: lafrenz m. J Hepatol. 2003 Oct;39(4):606-13. doi: 10.1016/s0168-8278(03)00298-8. J Hepatol. 2003. PMID: 12971972 Clinical Trial.
Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial.
Berg T, Hoffmann RM, Teuber G, Leifeld L, Lafrenz M, Baumgarten R, Spengler U, Zeuzem S, Pape GR, Hopf U. Berg T, et al. Among authors: lafrenz m. Liver. 2000 Dec;20(6):427-36. doi: 10.1034/j.1600-0676.2000.020006427.x. Liver. 2000. PMID: 11169056 Clinical Trial.
Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial.
Witthöft T, Möller B, Wiedmann KH, Mauss S, Link R, Lohmeyer J, Lafrenz M, Gelbmann CM, Hüppe D, Niederau C, Alshuth U. Witthöft T, et al. Among authors: lafrenz m. J Viral Hepat. 2007 Nov;14(11):788-96. doi: 10.1111/j.1365-2893.2007.00871.x. J Viral Hepat. 2007. PMID: 17927615 Free PMC article. Clinical Trial.
53 results